New York, NY -- (SBWIRE) -- 03/29/2018 -- Overview
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/2740087-retinitis-pigmentosa-retinitis-pipeline-review-h2-2017
The Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 9, 3, 1, 25 and 9 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 10 molecules, respectively.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Global Markets Direct Report Coverage 7
Retinitis Pigmentosa (Retinitis) - Overview 8
Retinitis Pigmentosa (Retinitis) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 28
2-BBB Medicines BV 28
Acucela Inc 28
Allergan Plc 28
Amarantus Bioscience Holdings Inc 29
Amgen Inc 29
Applied Genetic Technologies Corp 30
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2740087-retinitis-pigmentosa-retinitis-pipeline-review-h2-2017
About Wise Guy Reports
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.